CytomX says FDA grants Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer - CTMX News | RalliesCytomX says FDA grants Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer
C
CTMX• FDA Fast Track designation for Varseta-M
- CytomX received FDA Fast Track designation for Varseta-M in relapsed or refractory metastatic colorectal cancer.
- Varseta-M is an EpCAM-targeted antibody-drug conjugate with a topoisomerase-1 inhibitor payload.
- A potential monotherapy registrational study is planned to start in 1H 2027.
•
